Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

NCT03433703 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
8
Enrollment
INDUSTRY
Sponsor class

Stopped Study recruitment was stopped due to difficulty in enrolling the targeted number of participants.

Conditions

Interventions

Sponsor

Eisai Inc.